Hims & Hers, the telehealth and wellness company, has hired a veteran of the autonomous vehicle industry as its next chief ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our Small-Cap Growth Investor model based on the ...

Fintel reports that on April 29, 2025, TD Cowen downgraded their outlook for Hims & Hers Health (NYSE:HIMS) from Buy to Hold. Analyst Price Forecast Suggests 29.49% Upside As of April 24 ...

Hims & Hers Health, Inc. (HIMS) shares soared 23% in the last trading session to close at $35.04. The move was backed by solid volume with far more shares changing hands than in a normal session.

Online telehealth companies like Hims & Hers and Ro, better known for sale of erectile disfunction and hair loss drugs, were able to sell copycats as self-pay drugs at huge discounts while ...

In a joint venture with Novo Nordisk, Hims & Hers will dispense all doses of Wegovy to Americans who buy eligible subscriptions, with plans starting at $599 a month. The offering will launch this ...

Novo Nordisk A/S is partnering with telehealth companies including Hims & Hers Health Inc., LifeMD Inc., and Ro to offer weight-loss drug Wegovy at lower price. Novo Nordisk A/S is partnering with ...

Shares of Hims & Hers Health (NYSE: HIMS) and LifeMD (NASDAQ: LFMD) are surging on Tuesday. The companie' stocks had jumped 24% and 34%, respectively, as of 3:15 p.m. ET as the S&P 500 and the ...

The providers -- Hims & Hers Health, Ro, and LifeMD -- will be shipping the weight-loss medication to patients’ homes. Patients who don’t have health insurance coverage for the weekly ...

Shelby Knowles / Bloomberg / Getty Images Hims & Hers Health shares surged Tuesday as the company announced a partnership with Danish drugmaker Novo Nordisk. Hims & Hers users will have access to ...

Shares of online pharmacy Hims & Hers surged after it struck a deal with Danish obesity drug maker Novo Nordisk to sell its Wegovy drug in the U.S. In a joint venture with Novo Nordisk ...